Obstetrics, Gynecology and Reproduction

Advanced search

Vaginal biocenosis in pregnant women with recurrent bacterial vaginosis after treatment with recombinant human interferon alpha-2b

Full Text:


Introduction. Preventing recurrent bacterial vaginosis (BV) during pregnancy is an important issue in current obstetrics.

Aim: to assess the effect of recombinant human interferon alpha-2b on the incidence of recurrent BV during pregnancy and on the bacterial, cytokine, and antimicrobial components of the nonspecific vaginal immunity.

Materials and methods. The study included 80 pregnant women with recurrent BV, 40 of whom (the main group) were treated with recombinant human interferon alpha-2b in the first half of pregnancy and after 30 weeks of pregnancy in addition to standard therapy (metronidazole or clindamycin). The other 40 women (control group) did not receive this interferon drug. Patients of the both groups were examined for the rate of BV recurrence and also tested for their vaginal bacteria and levels of β-defensin-2 (HBD-2), interleukin-1β (IL-1β), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and interferon-γ (INF-γ) in the third trimester of pregnancy.

Results. Treatment with recombinant human interferon alfa-2b led to a 3-fold reduction in the occurrence of repeated episodes of BV and an increase in the content of lactobacilli (7.24 ± 0.33 and 7.03 ± 0.40 in patients with interferon therapy and without it, respectively; p = 0.013) mainly due to Lactobacillus crispatus (7.14 ± 0.69 in women who received interferon alfa-2b, compared with 6.36 ± 0.95 in patients on standard therapy; p = 0.003) and a decrease in the number of some types of anaerobes. Also, the use of interferon alpha-2b in pregnant women with recurrent BV led to an increase in the content of IL-1β by 2.5 times, IL-6 by 3.5 times, IL-10 by 1.5 times, INF-γ by 2 times, and HBD-2 by 4 times.

Conclusion. Treatment of recurrent BV during pregnancy with recombinant human interferon alfa-2b, aimed at boosting the nonspecific vaginal immunity helps reduce the incidence of recurrent BV.

About the Authors

A. V. Podgornaya
Siberian State Medical University, Health Ministry of Russian Federation
Russian Federation

Anna V. Podgornaya – Assistant, Department of Obstetrics and Gynecology

Researcher ID: O-2754-2016

2 Moskovskiy trakt, Tomsk 634050

A. Sh. Makhmutkhodzhaev
Siberian State Medical University, Health Ministry of Russian Federation
Russian Federation

Alisher Sh. Makhmutkhodzhaev – MD, PhD, Professor, Department of Obstetrics and Gynecology

2 Moskovskiy trakt, Tomsk 634050


1. Makletsova S.A., Ryabinkina T.S. Bacterial vaginosis: the visible horizons of the problem and the prospects for the diagnosis and treatment of bacterial vaginosis: what experts say. [Bakterial'nyj vaginoz: vidimye gorizonty problemy i perspektivy diagnostiki i lecheniya bakterial'nogo vaginoza: chto govoryat eksperty]. StatusPraesens. Ginekologiya, akusherstvo, besplodnyj brak. 2014;(3):47–57. (In Russ.).

2. Kira E.F., Molchanov O.L., Semenova K.E. Biological role of lactic acid in the stability of the vaginal microecosystem. [Biologicheskaya rol' molochnoj kisloty v obespechenii stabil'nosti mikroekosistemy vlagalishcha]. Akusherstvo i ginekologiya. 2014;(12):31–6. (In Russ.).

3. Breshears L.M., Edwards V.L., Ravel J., Peterson M.L. Lactobacillus crispatus inhibits growth of Gardnerella vaginalis and Neisseria gonorrhoeae on a porcine vaginal mucosa model. BMC Microbiol. 2015;15:276. DOI: 10.1186/s12866-015-0608-0.

4. Zodzika J., Rezeberga D., Donders G. et al. Impact of vaginal ascorbic acid on abnormal vaginal microflora. Archiv Gynecol Obstet. 2013;288(5):1039–44. DOI: 10.1007/s00404-013-2876-y.

5. Probiotics and prebiotics. Global Practical Recommendations of the World Gastroenterological Organization. [Probiotiki i prebiotiki. Global'nye prakticheskie rekomendacii Vsemirnoj Gastroenterologicheskoj Organizacii]. World Gastroenterology Organisation, 2017. 37 s. (In Russ.). Available at:

6. McFarland L.V. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014;4(8):e005047. DOI: 10.1136/bmjopen-2014-005047.

7. Mastromarino P., Vitali B., Mosca L. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol. 2013;36(3):229–38.

8. Dukhanina M.V., Mazurkevich M.V., Firsova T.A. et al. Ways to solve the problems of bacterial vaginosis in practice of an obstetrician/gynecologist’s practice. [Puti resheniya problemy bakterial'nogo vaginoza v praktike vracha akushera-ginekologa]. Akusherstvo i ginekologiya. 2016;(1):101–8. (In Russ.). DOI: 10.18565/aig.2016.1.101-108.

9. Stute P., May T.W., Masur C., Schmidts-Winkler I.M. Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial. Climacteric. 2015;18(4):582–9. DOI: 10.3109/13697137.2015.1036854.

10. Tikhomirov A.L., Kazenashev V.V., Sarsaniya S.I., Tuskaev K.S. Prebiotic correction in bacterial vaginosis. [Prebioticheskaya korrekciya pri bakterial'nom vaginoze]. Medicinskij sovet. 2017;(2):66–8. (In Russ.).

11. Provotorova T.V., Minaev N.N. Interferon alfa as part of combination treatment for bacterial vaginosis. [Primenenie preparata interferona al'fa v kombinirovannoj terapii bakterial'nogo vaginoza]. Doktor.Ru. 2015;(S2):25–8. (In Russ.).

12. Podgornaya A.V., Makhmutkhodjaev A.Sh., Kokh L.I. et al. Nonspecific vaginal immunity in pregnant women with recurrent bacterial vaginosis. [Nespecificheskij immunitet vlagalishcha u beremennyh zhenshchin s recidiviruyushchim bakterial'nym vaginozom]. Sovremennye problemy nauki i obrazovaniya. 2017;(1). (In Russ.). Available at:


For citations:

Podgornaya A.V., Makhmutkhodzhaev A.S. Vaginal biocenosis in pregnant women with recurrent bacterial vaginosis after treatment with recombinant human interferon alpha-2b. Obstetrics, Gynecology and Reproduction. 2019;13(3):211-216. (In Russ.)

Views: 841

ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)